Professional
Added to YB: 2024-02-15
Pitch date: 2024-02-13
BIIB [bullish]
Biogen Inc.
-22.58%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Market Cap
$24.8B
Pitch Price
$227.01
Price Target
303.00 (+74%)
Dividend
N/A
EV/EBITDA
7.78
P/E
15.38
EV/Sales
2.72
Sector
Biotechnology
Category
growth
Show full summary:
Biogen Inc.: Maintaining Our $303 Fair Value Estimate as New Launches Ramp in 2024
BIIB $303 FV intact on better '24 margin outlook despite slow Leqembi rollout; neuro pipeline w/ SMA, ALS, PPD supports wide moat; Eisai/Ionis collabs key; $5.9B net debt to fund M&A; High risk from concentrated bets but regulatory/pricing mgmt
Read full article (10 min)